公开(公告)号：US12121499B2

公开(公告)日：2024-10-22

申请号：US17576868

申请日：2022-01-14

Applicant: GW Pharma Limited

Inventor： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC: A61K31/05 ,  A61K31/045 ,  A61K31/352 ,  A61K31/353 ,  A61K36/185 ,  A61K45/06

CPC classification number: A61K31/05 ,  A61K31/045 ,  A61K31/352 ,  A61K31/353 ,  A61K36/185 ,  A61K45/06 ,  A61K31/05 ,  A61K2300/00 ,  A61K31/045 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US20220387347A1

公开(公告)日：2022-12-08

申请号：US17576868

申请日：2022-01-14

Applicant: GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

Inventor： Benjamin WHALLEY ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC: A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US09962341B2

公开(公告)日：2018-05-08

申请号：US15321766

申请日：2015-06-26

Applicant: GW Pharma Limited

Inventor： Colin Stott ,  Marnie Duncan ,  Thomas Hill

IPC: A61K31/05

CPC classification number: A61K31/05 ,  A61K2300/00

Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).

公开(公告)号：US11318109B2

公开(公告)日：2022-05-03

申请号：US16709401

申请日：2019-12-10

Applicant: GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

Inventor： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC: A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US20170143642A1

公开(公告)日：2017-05-25

申请号：US15321766

申请日：2015-06-26

Applicant: GW Pharma Limited

Inventor： Colin Stott ,  Marnie Duncan ,  Thomas Hill

IPC: A61K31/05

CPC classification number: A61K31/05 ,  A61K2300/00

Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).